MedElevator
Войти в исследования Volunteers or victims: patients' views of randomised cancer clinical trials.
Аннотация
Randomised clinical trials are essential for the objective evaluation of different treatment strategies in cancer. However, in the field of oncology, very few of the eligible patients are entered into trials, and most treatments have only been tested on a small percentage of patients. For doctors, a major deterrent to participating in trials is the lack of resources--particularly time, but often also the local facilities. This report suggests that patients themselves are willing to take part in clinical research, and are attracted by being treated by a doctor with a specialist interest in the disease and encouraged by the possibility that their progress will be monitored closely. With the recent NHS changes, it is timely for the Department of Health and other national health departments to consider carefully what can be done to ensure that no new treatments are adopted without effective evaluation. This will require departments of health to identify and implement ways to facilitate accrual of appropriate numbers of patients onto research protocols (whether non-randomised phase I or phase II studies or large, multicentre phase III trials) over short time periods.
Перевод полного текста: Перевод в очереди
Полный текст источника
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
Angell M. Patients' preferences in randomized clinical trials. N Engl J Med. 1984 May 24;310(21):1385–1387. doi: 10.1056/NEJM198405243102111.
Antman K., Amato D., Wood W., Carson J., Suit H., Proppe K., Carey R., Greenberger J., Wilson R., Frei E., 3rd Selection bias in clinical trials. J Clin Oncol. 1985 Aug;3(8):1142–1147. doi: 10.1200/JCO.1985.3.8.1142.
Baum M. New approach for recruitment into randomised controlled trials. Lancet. 1993 Mar 27;341(8848):812–813. doi: 10.1016/0140-6736(93)90573-y.
Cassileth B. R., Zupkis R. V., Sutton-Smith K., March V. Informed consent -- why are its goals imperfectly realized? N Engl J Med. 1980 Apr 17;302(16):896–900. doi: 10.1056/NEJM198004173021605.
Davis S., Wright P. W., Schulman S. F., Hill L. D., Pinkham R. D., Johnson L. P., Jones T. W., Kellogg H. B., Jr, Radke H. M., Sikkema W. W. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer. 1985 Oct 1;56(7):1710–1718. doi: 10.1002/1097-0142(19851001)56:7<1710::aid-cncr2820560741>3.0.co;2-t.
Friedman M. A., Cain D. F. National Cancer Institute sponsored cooperative clinical trials. Cancer. 1990 May 15;65(10 Suppl):2376–2382. doi: 10.1002/1097-0142(19900515)65:10+<2376::aid-cncr2820651504>3.0.co;2-a.
Gotay C. C. Accrual to cancer clinical trials: directions from the research literature. Soc Sci Med. 1991;33(5):569–577. doi: 10.1016/0277-9536(91)90214-w.
Karjalainen S., Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ. 1989 Oct 28;299(6707):1069–1072. doi: 10.1136/bmj.299.6707.1069.
Mackillop W. J., Palmer M. J., O'Sullivan B., Ward G. K., Steele R., Dotsikas G. Clinical trials in cancer: the role of surrogate patients in defining what constitutes an ethically acceptable clinical experiment. Br J Cancer. 1989 Mar;59(3):388–395. doi: 10.1038/bjc.1989.78.
Penman D. T., Holland J. C., Bahna G. F., Morrow G., Schmale A. H., Derogatis L. R., Carnrike C. L., Jr, Cherry R. Informed consent for investigational chemotherapy: patients' and physicians' perceptions. J Clin Oncol. 1984 Jul;2(7):849–855. doi: 10.1200/JCO.1984.2.7.849.
Simes R. J., Tattersall M. H., Coates A. S., Raghavan D., Solomon H. J., Smartt H. Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br Med J (Clin Res Ed) 1986 Oct 25;293(6554):1065–1068. doi: 10.1136/bmj.293.6554.1065.
Smyth J. F., Mossman J., Hall R., Hepburn S., Pinkerton R., Richards M., Thatcher N., Box J. Conducting clinical research in the new NHS: the model of cancer. United Kingdom Coordinating Committee on Cancer Research. BMJ. 1994 Aug 13;309(6952):457–461. doi: 10.1136/bmj.309.6952.457.
Tannock I. F. Some problems related to the design and analysis of clinical trials. Int J Radiat Oncol Biol Phys. 1992;22(5):881–885. doi: 10.1016/0360-3016(92)90783-e.
Taylor K. M., Margolese R. G., Soskolne C. L. Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med. 1984 May 24;310(21):1363–1367. doi: 10.1056/NEJM198405243102106.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.